Day One Announces FDA Acceptance Of NDA And Priority Review For Tovorafenib In Relapsed Or Progressive Pediatric Low-Grade Glioma (pLGG)
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals has announced that the FDA has accepted its New Drug Application (NDA) and granted priority review for Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma (pLGG).
October 30, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One's stock may see positive movement due to the FDA's acceptance of its NDA and priority review for Tovorafenib, a treatment for pLGG.
The FDA's acceptance of Day One's NDA and priority review for Tovorafenib indicates a significant regulatory milestone for the company. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100